Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]

Xinxue Liu¹, Alasdair Ps Munro², Shuo Feng¹, Leila Janani³, Parvinder K Aley⁴, Gavin Babbage⁵, David Baxter⁶, Marcin Bula⁷, Katrina Cathie², Krishna Chatterjee⁸, Wanwisa Dejnirattisai⁹, Kate Dodd⁷, Yvanne Enever¹⁰, Ehsaan Qureshi¹¹, Anna L Goodman¹², Christopher A Green¹¹, Linda Harndahl¹³, John Haughney¹⁴, Alexander Hicks¹³, Agatha A van der Klaauw¹⁵, Jonathan Kwok¹⁶, Vincenzo Libri¹⁷, Martin J Llewelyn¹⁸, Alastair C McGregor¹⁹, Angela M Minassian²⁰, Patrick Moore²¹, Mehmood Mughal⁶, Yama F Mujadidi²², Kyra Holliday²³, Orod Osanlou²⁴, Rostam Osanlou²⁵, Daniel R Owens², Mihaela Pacurar², Adrian Palfreeman²⁶, Daniel Pan²⁶, Tommy Rampling¹⁷, Karen Regan²⁷, Stephen Saich⁵, Teona Serafimova²⁸, Dinesh Saralaya²⁷, Gavin R Screaton⁹, Sunil Sharma¹⁸, Ray Sheridan²⁹, Ann Sturdy¹⁹, Piyada Supasa⁹, Emma C Thomson³⁰, Shirley Todd²⁹, Chris Twelves²³, Robert C Read², Sue Charlton³¹, Bassam Hallis³¹, Mary Ramsay³², Nick Andrews³², Teresa Lambe¹, Jonathan S Nguyen-Van-Tam³³, Victoria Cornelius³, Matthew D Snape⁴, Saul N Faust³⁴; COV-BOOST study group

Affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
² NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
³ Imperial Clinical Trials Unit, Imperial College London, London, UK.
⁴ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
⁵ NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
⁶ Stockport NHS Foundation Trust, Stockport, UK.
⁷ NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
⁸ NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁹ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹⁰ PHARMExcel, Welwyn Garden City, Hertfordshire, UK.
¹¹ NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
¹² Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
¹³ Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
¹⁴ Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK.
¹⁵ Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK.
¹⁶ Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK.
¹⁷ NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁸ University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
¹⁹ Department of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK.
²⁰ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
²¹ The Adam Practice, Poole, UK.
²² NIHR Oxford Biomedical Research Centre, Oxford, UK.
²³ NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
²⁴ Public Health Wales, Betsi Cadwaladr University Health Board, Bangor University, Bangor, UK.
²⁵ University of Liverpool, Liverpool, UK.
²⁶ University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK.
²⁷ Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
²⁸ Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK.
²⁹ Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
³⁰ Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK; MRC University of Glasgow Centre for Virus Research, Glasgow, UK.
³¹ UK Health Security Agency, Porton Down, UK.
³² UK Health Security Agency, Colindale, London, UK.
³³ Division of Epidemiology and Public Health, University of Nottingham School of Medicine, UK.
³⁴ NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Electronic address: s.faust@soton.ac.uk.

PMID: 37055303
PMCID: PMC10089831
DOI: 10.1016/j.jinf.2023.03.025

Published Erratum

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]

Xinxue Liu et al. J Infect. 2023 May.

. 2023 May;86(5):540-541.

doi: 10.1016/j.jinf.2023.03.025. Epub 2023 Apr 12.

Authors

Affiliations

¹ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
² NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
³ Imperial Clinical Trials Unit, Imperial College London, London, UK.
⁴ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK.
⁵ NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
⁶ Stockport NHS Foundation Trust, Stockport, UK.
⁷ NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK.
⁸ NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
⁹ Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
¹⁰ PHARMExcel, Welwyn Garden City, Hertfordshire, UK.
¹¹ NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
¹² Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
¹³ Portsmouth Hospitals University NHS Trust, Portsmouth, UK.
¹⁴ Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK.
¹⁵ Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK.
¹⁶ Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK.
¹⁷ NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁸ University Hospitals Sussex NHS Foundation Trust, Brighton, UK.
¹⁹ Department of Infectious Diseases and Tropical Medicine, London Northwest University Healthcare, London, UK.
²⁰ Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
²¹ The Adam Practice, Poole, UK.
²² NIHR Oxford Biomedical Research Centre, Oxford, UK.
²³ NIHR Leeds Clinical Research Facility, Leeds Teaching Hospitals Trust and University of Leeds, Leeds, UK.
²⁴ Public Health Wales, Betsi Cadwaladr University Health Board, Bangor University, Bangor, UK.
²⁵ University of Liverpool, Liverpool, UK.
²⁶ University Hospitals of Leicester NHS Trust, University of Leicester, Leicester, UK.
²⁷ Bradford Institute for Health Research and Bradford Teaching Hospitals NHS Foundation Trust, Bradford, UK.
²⁸ Department of Infection, Guy's and St Thomas' NHS Foundation Trust, London, UK.
²⁹ Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, UK.
³⁰ Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK; MRC University of Glasgow Centre for Virus Research, Glasgow, UK.
³¹ UK Health Security Agency, Porton Down, UK.
³² UK Health Security Agency, Colindale, London, UK.
³³ Division of Epidemiology and Public Health, University of Nottingham School of Medicine, UK.
³⁴ NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK. Electronic address: s.faust@soton.ac.uk.

PMID: 37055303
PMCID: PMC10089831
DOI: 10.1016/j.jinf.2023.03.025

No abstract available

PubMed Disclaimer

Erratum for

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dejnirattisai W, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Serafimova T, Saralaya D, Screaton GR, Sharma S, Sheridan R, Sturdy A, Supasa P, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, Nguyen-Van-Tam JS, Cornelius V, Snape MD, Faust SN; COV-BOOST study group. Liu X, et al. J Infect. 2022 Jun;84(6):795-813. doi: 10.1016/j.jinf.2022.04.018. Epub 2022 Apr 9. J Infect. 2022. PMID: 35405168 Free PMC article. Clinical Trial.

Publication types

Actions

Grants and funding

MC_UU_00004/04/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]

Affiliations

Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511]

Authors

Affiliations

Erratum for

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources